Home / Resource Library / Cellular and humoral immune response to SARS‑CoV‑2 mRNA vaccines in patients treated with either Ibrutinib or RituximabCellular and humoral immune response to SARS‑CoV‑2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab